Immunome (NASDAQ:IMNM) Receives “Outperform” Rating from Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research note issued to investors on Thursday,Benzinga reports. They currently have a $33.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 286.15% from the company’s current price.

A number of other analysts have also recently weighed in on IMNM. Lifesci Capital assumed coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Stephens reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a report on Thursday. Finally, Guggenheim dropped their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $25.50.

Immunome Stock Down 0.3 %

Shares of NASDAQ:IMNM traded down $0.02 on Thursday, reaching $8.55. 126,965 shares of the company’s stock were exchanged, compared to its average volume of 865,106. The firm has a market capitalization of $681.77 million, a price-to-earnings ratio of -1.05 and a beta of 1.93. Immunome has a fifty-two week low of $8.30 and a fifty-two week high of $26.70. The business’s 50-day moving average is $9.84 and its two-hundred day moving average is $11.64.

Immunome (NASDAQ:IMNM) last issued its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The business had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. Analysts predict that Immunome will post -2.21 earnings per share for the current fiscal year.

Insider Activity

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

A number of hedge funds have recently bought and sold shares of IMNM. Victory Capital Management Inc. lifted its stake in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares in the last quarter. Intech Investment Management LLC bought a new position in Immunome during the third quarter valued at approximately $219,000. Primecap Management Co. CA raised its position in Immunome by 4.5% during the third quarter. Primecap Management Co. CA now owns 280,800 shares of the company’s stock valued at $4,105,000 after acquiring an additional 12,000 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Immunome by 217.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Finally, Cerity Partners LLC raised its position in Immunome by 10.5% during the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock valued at $776,000 after acquiring an additional 5,043 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.